ImmuneOncia Therapeutics, Inc.
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2016-09-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.immuneoncia.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
- Conditions
- TMB-HHistologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06365840
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT05276310
- Locations
- 🇰🇷
National Cancer Center, Ilsan, Korea, Republic of
🇰🇷Asan Medical Center, Republic of Korea, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
- Conditions
- Extranodal NK/T-cell LymphomaExtranodal NK/T-cell Lymphoma, Nasal Type
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04414163
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Gwangju, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
- Conditions
- Solid TumorLymphoma
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04306224
- Locations
- 🇺🇸
Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03644056
- Locations
- 🇰🇷
ImmuneOncia, Yongin-si, Gyeonggi-do, Korea, Republic of